reports
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
RDNT RADNET INC.
PBF PBF ENERGY INC. CLASS A
ORCL ORACLE CORPORATION
OMI OWENS & MINOR INC.
NEOG NEOGEN CORPORATION
MOD MODINE MANUFACTURING COMPANY
LGND LIGAND PHARMACEUTICALS INCORPORATED
KEY KEYCORP
CVGW CALAVO GROWERS INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
LPG DORIAN LPG
IRIX IRIDEX CORP.
USB US BANCORP
WHF WHITEFIELD
ADC AGREE REALTY CORPORATION
CNFR CONIFER HOLDINGS
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
LIND LINDBLAD EXPEDITIONS HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
ALOT ASTRONOVA INC.
FBK FB FINANCIAL CORPORATION
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
FEIM FREQUENCY ELECTRONICS INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ESQ ESQUIRE FINANCIAL HOLDINGS
BCDA BIOCARDIA
MCFT MASTERCRAFT BOAT HOLDINGS
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
PKE PARK AEROSPACE CORPORATION
DYNR DYNARESOURCE INC.
ALLY GMAC LLC
LPI LAREDO PETROLEUM INC.
KROS KEROS THERAPEUTICS
ASAN ASANA
PCVX VAXCYTE
NUVB NUVATION BIO INC (A)
SMMT SUMMIT THERAPEUTICS INC
BYRN BYRNA TECHNOLOGIES INC
UPST UPSTART HOLDINGS
HUMA HUMACYTE INC
BFZ BLACKROCK CALIF MUN INCOME TRUST
PEPG PEPGEN INC
PROK PROKIDNEY CORP.
GTE GRAN TIERRA ENERGY INC.
SBGI SINCLAIR INC
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
DMA DESTRA MULTI ALTERNATIVE FUND
ADVM ADVERUM BIOTECHNOLOGIES INC.
NUTX NUTEX HEALTH INC
SCND SCIENTIFIC INDUSTRIES INC
BATRK LIBERTY MEDIA CORPORATION
NBY NOVABAY PHARMACEUTICALS INC.
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
NEOG NEOGEN CORPORATION
CFFN CAPITOL FEDERAL FINANCIAL INC.
IRIX IRIDEX CORP.
GCBC GREENE COUNTY BANCORP INC.
JELD JELD-WEN HOLDING INC.
BCDA BIOCARDIA
JBHT J.B. HUNT TRANSPORT SERVICES
DNUT INC.
SONM KRISPY KREME INC
GREE SONIM TECHNOLOGIES INC
GREENIDGE GENERATION HLDGS INC
Texas Pacific Land Corp: 1 director
A director at Texas Pacific Land Corp bought 12 shares at 1,259.730USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
- Jonathan Moreland
PEB PEBBLEBROOK HOTEL TRUST
MTDR MATADOR RESOURCES COMPANY
JCOM J2 GLOBAL INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUN HUNTSMAN CORPORATION
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
ETSY ETSY INC.
ECPG ENCORE CAPITAL GROUP INC.
DAKT DAKTRONICS INC.
ASYS AMTECH SYSTEMS INC.
ARCC ARES CAPITAL CORPORATION
CMCO COLUMBUS MCKINNON CORPORATION
FMC FMC CORPORATION
MAC MACERICH COMPANY
WVE WAVE LIFE SCIENCES
PLBC PLUMAS BANCORP
FBK FB FINANCIAL CORPORATION
CWH CAMPING WORLD HOLDINGS INC. CLASS A
FLGT FULGENT GENETICS
PK PARK HOTELS & RESORTS INC.
FTDR FRONTDOOR INC.
AX AXOS FINANCIAL INC.
STRA STRATEGIC EDUCATION INC.
LBSRD LIBERTY STAR URANIUM & METALS
BCDA BIOCARDIA
ALEC ALECTOR
AMCR AMCOR PLC
RVLV REVOLVE GROUP
GO GROCERY OUTLET HOLDING
NOG NORTHERN OIL AND GAS
UAN CVR PARTNERS LP
PFX PHENIXFIN CORP
CLVT CLARIVATE PLC
KIND NEXTDOOR HLDGS INC
BHVN BIOHAVEN LTD
BHRB BURKE & HERBERT BANK & TR/VA
MAIA MAIA BIOTECHNOLOGY INC
AMWL AMERICAN WELL CORP
Agile Therapeutics Inc. Announces Completion of Acquisition by Insud P...
Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L. Agile Therapeutics has combined with Insud Pharma’s US Subsidiary, Exeltis USA, Inc., expanding an already significant women’s health/contraceptive portfolio Agile Therapeutics Common Shareholders to receive $1.52 per share of common stock Agile common stock will cease to be listed on the OTC QB PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (“Agile”) (OTCQB: AGRX), a women's healthcare company, today announced the completion of the acquisition of Agile by Insud Pharma, S.L. ...
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Ins...
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L. Agile Therapeutics will combine with Insud Pharma’s US Subsidiary, Exeltis, expanding an already significant Women’s Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to receive $1.52 per share of common stock – approximately a 356% premium to the closing share price on June 25, 2024 Definitive Merger Agreement is subject to Agile Shareholder Approval. Agile Board is recommending shareholder approval of the Definitive Merger Agreement PRINCETON, N.J., June 26, 2024 (GLOBE...
Agile Therapeutics Reports First Quarter 2024 Financial Results and Pr...
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. “We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sa...
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial R...
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pi...
Agile Therapeutics Announces Delisting from Nasdaq
Agile Therapeutics Announces Delisting from Nasdaq PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of a...
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year...
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024 Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial resu...
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financi...
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024 Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a...
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Bu...
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution Elimination of Remaining Debt to Perceptive Advisors Leaves the Company’s Balance Sheet Debt Free PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has paid-off the remainder of its debt facility with Perceptive Advisors (“Perceptive”). This significant milestone completes the repayment schedule contemplated by the Loan Agreement between the Company and Perceptive, which ori...
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gro...
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,892,572 shares of common stock of the Company originally issued in July 2022 and May 2023, having an exercise price of $3.69 per share, at a reduced exercise price of $1.25 per share. The shares of comm...
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Pane...
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022 GAAP Operating Expenses for Full Year 2023 Expected to be in the Range of $30 to $31.5 Million, a Decrease of 47% to 44% C...
The Biden-Harris Administration Announces New Guidance to Enable Expan...
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women These Actions Follow Several Months of Activity by the Biden Administration to Strengthen Access to All FDA Approved Contraceptives as Defined in President Biden’s June 2023 Executive Order The Company Commends the Administration for their Continued Commitment to Reproductive Health PRINCETON, N.J., Jan. 23, 2024 (GLOBE NEWSWIRE)...
- Jonathan Moreland
Agile Therapeutics Provides Update on Actions Being Taken to Strengthe...
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps New Report Follows Several Months of Activity by the Biden Administration and Lawmakers to Strengthen Access to Contraception as Defined in President Biden’s June 2023 Executive Order Implementation of the Committee’s Recommendation Could Potentially Eliminate Financial Barriers for Contraceptive Products like...
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Pr...
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter 2024 Gross Margin Grows to 63% in Third Quarter 2023 from 58% in Second Quarter 2023 Company Reaffirms Expected Full Year 2023 Net Revenue of At Least $25 Million Management to Host Conference Call Today, Thursday, November 9, 2023 at 8:30 a.m. ET PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) --...
Agile Therapeutics to Report Third Quarter 2023 Financial Results and ...
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023 Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2023 financial results before the market open on Thursday, November 9, 2023. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update. E...
Agile Therapeutics Reports an Inducement Grant to New Chief Financial ...
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the granting of a previously disclosed inducement award to the Company’s newly appointed Chief Financial Officer, Scott Coiante. In accordance with Nasdaq Listing Rule 5635(c)(4), the award was approved by the Company's Compensation Committee and made as a material inducement to Mr. Coiante’s entry into employment with the Company. In ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.